IMMUNE RESPONSE PRESERVATION DURING CHEMOTHERAPEUTICAL SHEMES Russian patent published in 2022 - IPC A61K31/519 A61K39/395 A61P35/00 

FIELD: medicine; oncology.

SUBSTANCE: group of inventions relates to the field of medicine, namely to oncology; it is intended for the treatment of cancer. A selective inhibitor of cyclin-dependent kinase 4/6 (hereinafter – CDK4/6) of the formula I or its pharmaceutically acceptable salt is used for the treatment of a human with cancer. The specified use includes prescription to a subject of a therapeutical scheme containing an induction phase and a support phase. The induction phase includes one or more chemotherapeutical cycles including the administration to the human of effective amount of CDK4/6 inhibitor, administration to the human of effective amount of a chemotherapeutical agent, and administration to the human of effective amount of an inhibitor of immunological control points. At the same time, CDK4/6 inhibitor is administered only less than about 24 hours before the administration of the chemotherapeutical agent. The support phase includes one or more treatment cycles including the administration to the human of effective amount of the inhibitor of immunological control points. At the same time, the support phase is prescribed after the induction phase is ended. In another embodiment, the use of a selective inhibitor of cyclin-dependent kinase 4/6 (CDK4/6) of the formula I or its pharmaceutically acceptable salt is presented for the treatment of a human with small cell lung cancer.

EFFECT: use of the group of inventions allows for the induction of higher frequencies of tumor-specific memory T-cells, enhancing of the activation of T-cells and induced expression of anti-inflammatory cytokines, suppression of regulation of genes related to enhancing of immunosuppression, as well as reduction in intra-tumor regulatory T-cells in populations of CD4+ T-cells.

46 cl, 41 dwg, 3 tbl, 17 ex